In five years, Pfizer will most likely be in a better position than it is today as a business. That's basically what ...

Pfizer said the deal will add expertise and potential oral and injectable treatments. Pfizer CEO Albert Bourla noted in a statement from the drugmaker that there are more than 200 health ...

Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an ...